

Satellite Meeting: C3 Glomerulopathy Program

1130h-1135h	Welcome and Introduction	Richard Smith
Session One C3 glomerulopathy in 2019: <i>Where we are?</i>		Chair: Miquel Blasco
1135h-1155h	How we approach the condition and the patient in 2019 [Goal: present current diagnostic, evaluation and treatment strategies in the patient with native kidneys]	Marina Vivarelli
1155h-1205h	The current value of complement biomarkers in patient management [Goal: lightning talk on the current value of biomarkers in guiding clinical care]	Joshua Thurman
1205h-1215h	The challenges and outcomes of transplantation [Goal: present strategies used to determine whether/when to transplant in C3G]	Moglie Le Quintrec
Session Two CAUSES: <i>An update on pathogenesis</i>		Chair: Elena Goicoechea de Jorge
1215h-1225h	What is new from the mouse models [Goal: Lightning talk on highlights from xxx mouse]	Kevin Marchbank
1225h-1235h	What's new from mouse models: the <i>C3del923_924DG</i> mouse [Goal: Lightning talk on insights from the <i>C3del923_924DG</i> mouse]	Santiago Rodriguez de Cordoba
1235h-1250h	Update on acquired factors: C3Nefs, antibodies and paraproteins – predicting outcome [Goal: present the values of C3Nefs (and stabilizing ability) and paraproteins in predicting renal outcome]	Sophie Chauvet
1250h-1300h	Complement in the native and transplant kidney [Goal: lightning talk on expected complement findings in normal and transplanted kidneys]	Nicholas Medjeral-Thomas
1300h-1330h	DISCUSSION of SESSIONS ONE and TWO Moderators: Miquel Blasco and Elena Goicoechea de Jorge	Panelists
1330h-1430h	Lunch and Networking	

Session Three		Chair: Carla Nester
DIAGNOSIS: New insights		
1430h-1445h	Influence of conventional immunosuppression in renal survival: insights from GLOSEN [Goal: present expected outcomes normal and transplanted kidneys]	Manuel Praga
1445h-1500h	Diagnostic Conundrums: do we need to refine the criteria to diagnose C3G? [Goal: MPGN/ICGN/MGRS]	Vivette D'Agati
1500h-1515h	Complement, immunoglobulins and paraproteins: the variable expressions of C3 glomerulopathy [Goal: Describe the broad spectrum of biomarker findings that fall under the rubric of C3G]	Veronique Fremeaux-Bacchi
1515h-1530h	Defining the clinical picture with complement biomarkers and assays [Goal: Describe the potential power of comprehensive complement testing to refine understanding of C3G]	Richard Smith
1530-1600h	DISCUSSION of SESSION THREE Moderator: Carla Nester	Panelists
1600h-1630h	Coffee and Networking	
Session Four		Chair: Gerry Appel
TREATMENT: Trials on trial		
1630h-1650h	The Doctor's dilemma: The plethora of clinical trials: what to do [Goal: Review the available trial options and describe the challenges and ethical obligations to patient treatment]	Beppe Remuzzi
1650h-1710h	The Patient's perspective: Living with C3 glomerulopathy – messages from the patients [Goal: Review the resources available to the patients and their expectations in clinical trials]	Lynne Lanning
1710h-1730h	Update on the trials [Goal: Describe the current status in the USA]	Carla Nester
1730h-1800h	DISCUSSION of SESSION FOUR Moderator: Gerry Appel	Panelists
1800h-1825h	PHARMA Panel Moderator: Gerry Appel	Panelists Representatives from Pharma
1825h-1830h	Final Thoughts and Conclusions	Richard Smith
1830h	Meeting Close and Networking	